Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 14/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23525827 | 1.00 | SOS1 (0.41) | SOS1L3MBTL1MAPK1SMN1; SMN2CTSA | |
| SCHEMBL30014414 | 1.00 | SOS1 (0.41) | SOS1L3MBTL1MAPK1SMN1; SMN2CTSA | |
| SCHEMBL23525873 | 0.82 | SOS1 (0.43) | SOS1L3MBTL1MAPK1SMN1; SMN2CTSA | |
| SCHEMBL30014661 | 0.82 | SOS1 (0.43) | SOS1L3MBTL1MAPK1SMN1; SMN2CTSA | |
| SCHEMBL23525871 | 0.82 | SOS1 (0.43) | SOS1L3MBTL1MAPK1SMN1; SMN2CTSA | |
| SCHEMBL28880409 | 0.82 | TRPA1 (0.46) | — | |
| SCHEMBL23563447 | 0.82 | TRPA1 (0.46) | — | |
| SCHEMBL29945842 | 0.82 | TRPA1 (0.46) | — | |
| SCHEMBL25628057 | 0.79 | SOS1 (0.44) | SOS1 | |
| SCHEMBL23526447 | 0.76 | SOS1 (0.41) | SOS1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023250165-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023030216-A1 | QUINAZOLINE DERIVATIVE, OR PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2023-03-09 | — | — | WO | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | SOS1 1/4885L3MBTL1 519/4885MAPK1 576/4885 |
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | SOS1 1/4885L3MBTL1 1107/4885MAPK1 608/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | SOS1 1/4885L3MBTL1 1107/4885MAPK1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.